Video 6.4.2 from the course Personalised Medicine from a Nordic Perspective.

Why does the pharmaceutical industry invest in genetics and omics?  How has adding proteomics to genomics research provided key new insights to the identification of novel targets in relation to drug development? What if any, are the main ethical challenges that the pharmaceutical entity face at present when doing research in the field of genetics and omics? Engilbert Sigurdsson interviews Morten Søgaard, vice president and head at Target Sciences, Pfizer.

About the course:
The technical revolution enables us to analyse large amounts of data in healthcare and research and continuously increase our understanding of the complex factors that determine disease risk and outcome. This holds great potential to support a change from the one-size-fits-all paradigm to personalised or precision medicine. The Nordic countries have a well-functioning data infrastructure, which gives us the opportunity to be at the forefront of this revolution – especially if many healthcare professionals and researchers understand the potential. The course is developed by the University of Iceland and the University of Copenhagen in collaboration with medical faculties across the Nordic countries. It was initiated by Faculty leaders in the Education Working Group of Nordic Medical Schools and received funding from the Joint Committee of the Nordic Medical Research Councils (NOS-M).

Access to course materials:
The full course (including quizzes, readings and other resources) is available for free at Coursera.  
All 31 course videos are available for individual implementation and as a playlist at oer.ku.dk